A Randomized Phase 2 Study of HLX22 Plus Trastuzumab Biosimilar HLX02 and XELOX As First-Line Therapy for HER2-positive Advanced Gastric Cancer
Med（2024）
Key words
HLX22,HLX02,anti-HER2,trastuzumab biosimilar,gastric cancer,first-line,phase 2
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined